Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant

[1]  P. Neven,et al.  Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study , 2008, Breast Cancer Research and Treatment.

[2]  K. Altundag,et al.  From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  N. Harbeck,et al.  Endometrial safety of cross-over treatment with tamoxifen followed by exemestane , 2008 .

[4]  M. Piccart,et al.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Poole,et al.  The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review , 2007, Current opinion in oncology.

[6]  M. Lux,et al.  Fulvestrant: A Further Treatment Option for Patients with Metastatic Uterine Cancer? , 2006, Oncology Research and Treatment.

[7]  G. Garuti,et al.  Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors. , 2006, Gynecologic oncology.

[8]  R. Paridaens,et al.  Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  D. Timmerman,et al.  Aromatase Inhibitors and Postmenopausal Breast Cancer Patients with Tamoxifen-Induced Endometrial Pathology , 2006, Clinical Cancer Research.

[10]  G. Kundt,et al.  Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  M. Hoffman,et al.  Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. , 2006, Gynecologic oncology.

[12]  A. Bianco,et al.  The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. , 2006, Human reproduction.

[13]  P. Neven,et al.  Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting , 2005, Current opinion in oncology.

[14]  C. Osborne,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma , 2005, Cancer.

[15]  J. Robertson,et al.  Endocrine treatment options for advanced breast cancer--the role of fulvestrant. , 2005, European journal of cancer.

[16]  A. Gadducci,et al.  Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. , 2004, Current opinion in investigational drugs.

[17]  A. V. D. Van Der Zee,et al.  [The effects of tamoxifen on the female genital tract]. , 2003, Nederlands tijdschrift voor geneeskunde.

[18]  J. Donnez,et al.  A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. , 2003, Fertility and sterility.

[19]  R. J. Cersosimo.  Tamoxifen for Prevention of Breast Cancer , 2003, The Annals of pharmacotherapy.

[20]  R. Yates,et al.  A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers , 2002, British Journal of Cancer.

[21]  M. Berlière,et al.  Endometrial evaluation is a very important tool in the management of breast cancer patients. , 2002, European journal of cancer.

[22]  J. Robertson.  Faslodex (ICI 182, 780), a novel estrogen receptor downregulator—future possibilities in breast cancer , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[24]  P. Neven,et al.  Should tamoxifen users be screened for endometrial lesions? , 1998, The Lancet.

[25]  T. Bourne,et al.  Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.

[26]  P. Neven,et al.  TAMOXIFEN AND THE UTERUS AND ENDOMETRIUM , 1989, The Lancet.

[27]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .

[28]  D. Koeberle,et al.  Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations. , 2007, European journal of cancer.

[29]  I. Cohen,et al.  Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients , 2006, Breast Cancer Research and Treatment.

[30]  D. Timmerman,et al.  Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  T. Powles.  COMMENT ON: TAMOXIFEN FOR PREVENTION OF BREAST CANCER : REPORT OF THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT P-1 STUDY , 1999 .